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Abstract
Background: In breast cancer, ER/PgR, HER2, and Ki-67 are important biological markers for predicting prognosis
and making effective treatment decisions. In addition, changes in markers due to relapse are also clinically
experienced; however, the frequency and clinical significance are still not fully understood. Thus, changes in
markers and their correlations with prognosis were investigated.
Patients and Methods: Out of the patients with relapse from 1997 to March 2011, there were 97 consecutive
patients from whom the lesion was resected and evaluated by immunostaining. The biopsy sites were chest wall,
lymph node, ipsilateral breast tumor recurrence, lungs, bones, ovaries and brain. The markers sought were ER, PgR,
HER2, p53 and Ki-67.
Results: The hormone receptor positive rate from the primary tumor to recurrence decreased from 63.9% to 57.7%
and from 56.7% to 43.3% for ER and PgR, respectively. Changes in the positive/negative evaluation were seen at
the rate of 10.3% and 25.8% for ER and PgR, respectively. The Ki-67 index increased significantly from a mean of
29.1% at primary tumor to 36.3% at relapse. When divided into 2 groups (< 50% and ≥50%), changes were seen in
24.7%. On the other hand, the rates of changes in HER2 and p53 positivity were 14.4% and 12.4%. The changes in
subtypes were seen in 25%, however, the lowest rate of change was seen in the triple negative cases. Although
there was no notable difference in the rate of change between disease-free interval (DFI) and PgR, Ki-67, p53 and
HER2, there was a significant difference in the change rates in the ER. A multivariate analysis revealed that the
status of distant metastasis and PgR level at relapse, and Ki-67 levels at primary tumor were all significant factors.
Conclusion: Estrogen receptor and PgR decreased while Ki-67 increased due to relapse; however, the rate of
change was high for PgR and Ki-67. Change in the subtypes was seen in 25%. In addition, PgR at relapse and Ki-67
at primary tumor were significant factors for post-relapse prognosis while PgR becoming negative was a poor
prognostic factor. These findings are important for making effective treatment decisions.
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Background
Treatment decisions for breast cancer are commonly
made based on the information derived from the immu-
nohistochemistry (IHC) of biological markers. For exam-
ple, the application of chemotherapy is commonly used
for patients with high Ki-67 values, endocrine therapy
for ER positive, and anti-HER2 (trastuzumab) therapy
for HER2 positive have recently been recommended [1].
Post-operative adjuvant treatment decisions are com-
monly based on the IHC data at surgery. Moreover,
treatment decisions for recurrent cases are generally
based on ER and HER2 status at primary tumor, dis-
ease-free interval (DFI), recurrence site, and the perfor-
mance status [2]. Recently, surgical resection of
recurrent lesions followed by pathological confirmation
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is also being proposed for effective treatment decisions.
This biological change is due to the progression of
cancer and metastasis. The authors in most studies [3-5]
have stated that hormone receptors (HRs) change read-
ily while there are few changes in HER2. Furthermore,
there are also reports of changes in treatment in con-
junction with this change [6]. However, the mechanism
of this change is still relatively unknown and there are
only a few reports outlining the importance of the Ki-67
index and p53 overexpression. This study attempts to
contribute to this endeavor by measuring the biological
markers in recurrent breast cancer and then compare
them to the status at the primary tumor. Furthermore,
the involvement of this change in post-relapse prognosis
was also examined retrospectively.
Patients and methods
Out of all the patients with relapse during the period
from 1997 to March 2011, there were 97 consecutive
patients from whom the lesion was resected either by
surgery or biopsy and evaluated by immunostaining.
The baseline information of all the patients with recur-
rent breast cancer enrolled in this study is presented in
Table 1. The age of the patients ranged from 31 to 83
years old (median, 53 years). The median value for DFI
was 57.4 months, and the DFI for 45 patients (46.4%)
exceeded 5 years. The surgical sites were loco-regional
recurrences and ipsilateral breast tumor recurrence
(IBTR) for the majority of the patients. Exploration for
distant metastasis in the lungs (3 patients), brain (3
patients), bone (1 patient), and ovaries (3 patients) was
also performed. However, distant metastasis at surgery
for recurrence was explored in 33 (34.0%) patients. The
biological markers were as follows: ER positive rate was
63.9%, PgR positive rate was 56.7%, and HER2 and p53
overexpression was 22.7%. On the other hand, the med-
ian value of the Ki-67 index was 22.7%, which was
slightly higher than the median value of all the primary
cases [7]. To explore the biological markers in this
study, an informed consent was obtained from all the
patients at both the initial surgery and at the relapse
biopsy. Moreover, no new primary cases were included
in this study.
The post-surgery follow up and examination was per-
formed every 3 months until 3 years post-surgery, every
3-6 months until 3-5 years post-surgery, and every 6-12
months post-surgery from 5 years and onwards. In
some cases, the follow-up was continued even after 10
years post-surgery. Mammography, chest X-ray, CT
scan or abdominal ultrasound (US), and tumor marker
tests are performed at least once a year.
Postoperative adjuvant treatment is being performed
in accordance with the treatment recommendations of
Table 1 Characteristics of all patients with recurrent
breast cancer in this study
Characteristics Number Percent
Median age at diagnosis (years), range 53 (31 - 83)
Total 97
Tumor size at the primary tumor
≤ 2.0 cm 51 52.6
2.0 cm < 46 47.4
No. of positive nodes at the primary tumor
0 46 47.4
1-3 27 27.8
4≤ 21 21.6
Unknown 3 3.1
Nuclear grade at the primary tumor
1 16 16.5
2 50 51.5
3 19 19.6
Unknown 12 2.1
Lymphatic invasion at the primary tumor
0 27 27.8
1+ 51 52.6
2+ 17 17.5
Unknown 2 2.1
ER at the primary tumor
Positive 62 63.9
Negative 35 36.1
PgR at the primary tumor
Positive 55 56.7
Negative 42 43.3
HER2 at the primary tumor
Positive 22 22.7
Negative 75 77.3
p53 at the primary tumor
Positive 22 22.7
Negative 75 77.3
Ki-67 index at the primary tumor
Positive 12 12.4
Negative 85 87.6
DFI at recurrence
< 2 years 19 19.6
2-5 years 33 34.0
5 years ≤ 45 46.4
Sites of biopsied recurrence
Chest wall 39 40.2
In-breast 34 35.1
Regional lymph node 11 11.3
Lung 3 3.1
Bone 1 1.0
Brain 3 3.1
Ovary 3 3.1
Distant skin 3 3.1
Distant metastasis at biopsy
With 33 34.0
Without 64 66.0
Nishimura et al. World Journal of Surgical Oncology 2011, 9:131
http://www.wjso.com/content/9/1/131
Page 2 of 7the St. Gallen International Conference [1]. Endocrine
therapy is performed for ER/PgR positive cases and che-
motherapy for ER negative cases with or without lymph
node metastasis. In addition, trastuzumab treatment has
been performed for HER2 positive cases since 2008. For
the patients in this study, trastuzumab was not used as an
adjuvant therapy. However, it was used for patients with
recurrence from 2001. Due to the nature of different treat-
ments that require different lengths of time for effective
results, it was difficult to identify the correlation between
treatments and the changes in the biological markers.
Moreover, recurrence after treatment varies and therefore
it is difficult to summarize these treatment patterns.
Histopathological Examination
The items investigated were the presence or absence of
distant metastasis at biopsy or surgery for recurrent
lesions, ER/PgR status, proliferation (Ki-67), HER2, and
p53 overexpression. Immunostaining of ER, PgR, p53,
Ki-67 and HER2 was done as previously described [8].
Biological markers were examined at primary tumor
and biopsy or operation for recurrent lesions. The vari-
ables of interest were ER, PgR, HER2, Ki-67 labeling
index, and p53 overexpression. Hormone receptor posi-
tivity was defined by positive staining for estrogen- and/
or progesterone-positive receptors in at least 10% of the
tumor cell nuclei. HER2 expression was initially evalu-
ated using the Hercep Test (Dako, Glostrup, Denmark).
HER2 positivity was indicated by 3+ staining intensity.
HER2 equivocal (2+ staining) was tested using fluores-
cence in situ hybridization with a threshold ratio of > 2.0
for positive HER2:CEP17. Proliferation activity was
assessed by immunostaining with the Ki-67 antibody
(Dako). The proportion of proliferating cells was deter-
mined by counting at least 500 tumor cells. The median
value of Ki-67 index was 20% in all primary breast can-
cer, and the median value of TN tumors was 50% [7].
Moreover, higher values (≥50%) correlated with early
recurrence and unfavorable prognosis. Therefore, in this
study, the cases were divided into 2 groups; < 50% and
50%≤. Expression of p53 was also evaluated by immunos-
taining with the mouse monoclonal anti-p53 antibody
(clone DO7; Dako). The staining pattern of the p53 pro-
tein was divided into three groups, 2+ (homogenous and
diffuse staining), 1+ (heterogeneous or focal staining in >
5% of the tumor cells), and negative (focal staining in <
5% of the tumor cells). In this study, p53 overexpression
was indicated by 2+ staining. The subtypes were classified
as follows: HR positive and HER2 negative tumors were
classified as luminal A type; HR positive and HER2 posi-
tive tumors (HER2 IHC: 3+ or 2+ and FISH amplification
ratio > 2.0) as luminal B type; HR negative and HER2
positive tumors as HER2 disease; and HR negative and
HER2 negative tumors as the TN type.
Statistical Analysis
Statistical comparisons between groups were performed
using the Chi-square and Fisher’s exact tests. The Wilcox-
on’s (non-parametric) test was used to compare the mean
values for the Ki-67 index. The Kaplan-Meier test was used
to calculate prognosis (cumulative overall survival (OS)).
Cox’s proportional hazard model was used to perform uni-
variate and multivariate analyses of the factors related to
OS after recurrence. A two sided p value of < 0.05 was con-
sidered to be statistically significant. The median observa-
tion period after recurrence was 41.9 months.
Results
1. Changes in positive rate due to relapse of biological
markers
Changes due to relapse of a positive rate for each mar-
ker are shown in Table 2. There was a decrease in the
following hormone receptors; ER from 63.9% to 57.7%,
PgR from 56.7% to 43.3%, and there was only a marginal
difference for PgR. Moreover, the values for p53 and
HER2 changed from 22.7% to 24.7% and from 22.7% to
30.9%, respectively. Regarding Ki-67 index, the positive
rate significantly increased from 12.4% to 24.7%.
Furthermore, the mean value of 29.1% at primary tumor
increased notably to 36.3% at relapse.
2. Changes by category due to relapse of the biological
markers
Changes between categories of each marker are shown
in Table 3. Changing from positive to negative was
Table 2 Changes in biological marker status (positive
rates) between primary breast tumors and matched
recurrent lesions
Biological Markers Primary Recurrence p value
Positive rate (%)
Estrogen Receptor 62 (63.9) 56 (57.7) 0.46
Progesterone Receptor 55 (56.7) 42 (43.3) 0.08
p53 22 (22.7) 24 (24.7) 0.87
HER2 22 (22.7) 30 (30.9) 0.26
Ki-67 Index 12 (12.4) 24 (24.7) 0.012
(Ki-67: mean ± S.D.(%) 29.1 ± 18.5% 36.3 ± 21.0% < 0.0001 )
Table 1 Characteristics of all patients with recurrent
breast cancer in this study (Continued)
Median Ki-67 value (%) at the primary tumor,
range
27.0 (1-91)
Median DFI (months), range 57.4 (1-281)
DFI: disease-free interval, ER: estrogen receptor, PgR: progesterone receptor
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PgR in 24.8% of the patients. For p53 and HER2, chan-
ging to positive was common, but there was no notable
difference. On the other hand, the Ki-67 index had a
significantly higher rate of change from negative to posi-
tive (22.6%).
3. Changes in markers and DFI
Category changes for each marker and the correlation
with DFI are shown in Table 4. The rate of change was
4.4% for ER in patients with a DFI of at least 5 years,
and a significant difference was seen in patients with a
DFI of 5 years or less. However, DFI had no clear corre-
lation with PgR, Ki-67, p53, and HER2.
4. Changes in molecular subtypes
Changes in subtypes at primary tumor and relapse are
shown in Table 5. Looking at the discordance rates, the
values for luminal A and luminal B were high at 28.8%
and 33.3%, respectively, while the HER2 and Triple
Negative (TN) values were low at 18.7% and 16.7%,
respectively.
5. Investigation of prognosis and predictive factors after
recurrence
Cumulative survival rates post-relapse are shown in Fig-
ure 1. The rates for the 5- and 10-year OS were 63.5%
and 48%, respectively, indicating a good prognosis for
the study groups. Univariate and multivariate analyses
were performed on the OS-related factors of these
patients (Table 6). The univariate analysis revealed that
Ki-67 and PgR at primary tumors, and Ki-67, ER, PgR
and status of distant metastasis at recurrence were all
significant factors. Furthermore, the multivariate analysis
revealed that the status of distant metastasis at recur-
rence, Ki-67 at primary tumor, and PgR at recurrence
were all independent factors. All the available data at
recurrence was viewed as pertinent information for mul-
tivariate analysis.
Discussion
In this study, there were many cases of a decreased HR
positive rate due to relapse. The rate of change in posi-
tive/negative PgR was notable, with a decrease in the
rate of positive. On the other hand, the rates of change
for p53 and HER2 were low while that of the Ki-67
index category was high at 22.6%, clearly demonstrating
a high growth potential due to relapse. At our institu-
tion, the IHC evaluation is performed by two patholo-
gists under constant fixed conditions and operating
procedures to eliminate the possibility that the differ-
ence is due to a difference in evaluation methods.
According to recent reports [3-5], changes in ER and
PgR due to primary and relapse cancers are common.
However, there are only a few changes in HER2. In the
investigation of locoregional recurrence (LRR) [9], the
discordance rates between primary cancer and LRR was
9% for ER, 22% for PgR and 4% for HER2. In the BRITZ
and Destin studies [5], the data of 258 patients (locore-
gional relapse in 54% and distant metastases in 46%)
were compared, and the discordance rates for ER, PgR
and HER2 were 13%, 28% and 5%, respectively, showing
a notable discordance for PgR. Furthermore, the change
in TN cases was reported to be low. On the other hand,
in a prospective study [6] on 26 patients with distant
Table 3 Changes in biological marker status (category)
between primary breast tumors and matched recurrent
lesions
Marker Decrease Increase % Change p value p value
primary ® recurrence * PgR ** Ki-67
ER + ® -:8 -® + : 2 10/97 (10.3) 0.009 0.03
PgR + ® - : 19 - ® + : 6 25/97 (25.8)* 0.74
p53 + ® -:5 -® + : 7 12/97 (12.4) 0.028 0.09
HER2 + ® -:3 -® + : 11 14/97 (14.4) 0.073 0.20
Ki-67 Index + ® -:5 -® + : 17 22/97 (22.6)** 0.74
ER: estrogen receptor, PgR: progesterone receptor
Table 4 Changes in biological marker status (category)
between primary breast tumor and matched recurrent
lesions according to DFI
Marker/DFI Decrease Increase % Change p
primary ® recurrence value
ER
DFI < 2y + ® -:2 -® + : 1 3/19 (15.8)
2y < DFI < 5y + ® -:4 -® + : 1 5/33 (15.2) *p = 0.045
DFI > 5y + ® -:2 -® + : 0 2/45(4.4) * DFI < 5y
PgR
DFI < 2y + ® -:2 -® + : 3 5/19 (26.3)
2y < DFI < 5y + ® -:6 -® + : 1 7/33 (21.2) NS
DFI > 5y + ® - : 11 - ® + : 2 13/45 (28.9) (0.74)
Ki-67 Index
DFI < 2y + ® -:0 -® + : 5 5/19 (26.3)
2y < DFI < 5y + ® -:2 -® + : 6 8/33 (24.2) NS
DFI > 5y + ® -:3 -® + : 6 9/45 (20.0) (0.83)
p53
DFI < 2y + ® -:1 -® + : 0 1/19 (5.3)
2y < DFI < 5y + ® -:3 -® + : 2 5/33 (15.2) NS
DFI > 5y + ® -:1 -® + : 5 6/45 (13.3) (0.56)
HER2
DFI < 2y + ® -:0 -® + : 1 1/19 (5.3)
2y < DFI < 5y + ® -:1 -® + : 6 7/33 (21.2) NS
DFI > 5y + ® -:2 -® + : 4 6/45 (13.3) (0.28)
DFI: disease-free interval, ER: estrogen receptor, PgR: progesterone receptor
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(P = 0.003), and for Her2 status, in 8% of the patients.
B i o p s yr e s u l t sl e dt oac h a n g eo ft r e a t m e n ti n2 0 %o f
the patients (P = 0.002). In a retrospective study con-
ducted by the MDACC [10], the changes in ER, PgR,
and HER2 were 18.4%, 40.3%, and 13.6%, respectively.
In addition, the survival rate for the ER/PgR matching
cases was better than the non-matching cases. Further-
more, the discordant rates in a retrospective study [11]
on 255 cases of liver metastasis were ER:14.5%,
PgR:29.8%, and HER2:13.9%, and the treatment was
changed for 18.8% of the cases. The changes in ER and
particularly PgR, is notable ev e ni nl o c o r e g i o n a ll e s i o n s
as well as in distant lesions. On the other hand, the
change in HER2 was low. These results were similar to
those obtained in the present study. Treatment decisions
must take this change into consideration and that is why
we select our treatment depending on the condition of
the receptors.
Looking at the changes due to treatment based on the
Ki-67 index, the number of responders to endocrine
therapy as the neoadjuvant therapy decreased, and the
prognosis of the patients with decreased levels was good
[12]. In addition, the prognosis of patients with
decreased levels in post-chemotherapy was reported to
be good [13,14]. A decrease in the Ki-67 value was seen
in the patients that responded to treatment. Moreover,
in the comparison between primary tumors and meta-
static lymph nodes, the positive/negative (cutoff point:
20%) matching rate was reported to be 85% [15], and
t h e r ew e r eo n l yaf e wc h a n g e si nm a n yc a s e sw h e r e
treatment was not involved. Change at relapse in this
study was defined as patients who had a relapse after all
of the patients received chemotherapy and endocrine
therapy, and the relapse lesion did not respond to treat-
ment. Therefore, change in the Ki-67 value can reflect
the level of response towards treatment.
Many patients in this study had locoregional lesions
which could be biopsied and resected and the post-
relapse prognosis was assumed to be good for most of
the patients, and in fact, good OS was shown. Investiga-
tion of the prognostic factors in such patients using
multivariate analysis revealed that the Ki-67 index at
surgery and PgR at relapse were significant. PgR turning
negative is the first factor found after a relapse, indicat-
ing the significance and importance of these evaluations.
In addition, looking at the changes in the subtypes of
25% of the patients, the rate of change of the luminal
type was notable but the rate for TN was low. However,
luminal B in this study was defined as ER+/HER2+. If
there is a high Ki-67 value, even in HER2-, which is
defined as a criterion for luminal B type cancer, then
there will be more changes in many of the patients’ sub-
types. With regards to the prognosis, the prognosis
post-TN relapse was reported to be the worst. Patients
with TN breast cancer at LRR experienced a higher risk
of subsequent relapse [8]. Post-recurrence survival rates
were most favorable in concordant receptor-positive
patients for all three receptors. However, patients with
discordant receptor status had a similar unfavorable sur-
vival rate as patients with concordant TN breast cancer
[10]. Although gene expression profiling studies over
the past decade have established molecular subtypes, the
panel for IHC in a routine pathology setting is a priority
because of the current costs of such molecular testing.
The IHC is merely a surrogate method of indicating
such subtypes. Further research is needed to investigate
the relationship between molecular subtypes and
changes in biological markers.
Table 5 Changes in breast cancer subtype between primary breast tumors and matched recurrent lesions
Subtype/primary No. of cases Recurrent lesions Discordance %
Luminal A Luminal B HER2 TN
Luminal A 57 41 (71.2) 8 (14.0) 1 (1.8) 7 (12.3) 28.8
Luminal B 6 2 (33.3) 4 (66.7) 33.3
HER2 16 0 2 (12.5) 13 (81.3) 1 (6.3) 18.7
TN 18 1 (5.6) 0 2 (11.1) 15 (83.3) 16.7
Total 97 44 14 16 23 24.7
TN: Triple Negative
Figure 1 Overall Survival after Recurrence in the enrolled cases
The rates for the 5- and 10-year overall survival were 63.5% and
48%, respectively, indicating a good prognosis for the study groups.
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In conclusion, ER and PgR decreased while Ki-67 tended
to increase due to relapse; however, the rate of change
was high for PgR and Ki-67. In addition, patients with a
change in category had low levels for ER/p53/HER2 at
approximately 10%, but high levels for PgR and Ki-67 at
25.8% and 22.6%, respectively. On the other hand,
changes in ER were significantly fewer in patients with a
DFI > 5 years. Subtype changes due to relapse was seen
in 25% of the patients. Multivariable analysis revealed
that Ki-67 at primary tumor and PgR at relapse are sig-
nificant factors in post-relapse prognosis. Thus, though
changes in biological markers occur due to relapse,
pathological confirmation as well as exploration for
markers are important. It is particularly important to
note that PgR and Ki-67 change readily. A prospective
study is necessary to assess the clinical significance of
the changes in biological markers.
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